Description: Find out what roles reinsurance and reinsurance intermediaries play for ceding companies in need of capital and the providers of such capital.

Description: Discussion of solvency problems and the actuary's role in addressing them in the life insurance industry.

Description: In 2014, the SOA Product Development and Reinsurance Sections, along with the Committee for Life Insurance research engaged Reinsurance Group of America to undertake a research project on term conversion experience.

Description: This 1981 session focused on Reinsurance Trends. Questions included: i. Why the recent movement from YRT to Coinsurance? 2. Should a company use a bulk or self-administered system? 3. When is it advantageous to use Coinsurance or modified coinsurance on existing business? 4. Experimental Underwriting - what are the results? 5. Pricing assumptions - where have all the margins gone? 6. When can reinsurance pools be used effectively what are the pitfalls? 7. What's in the future? a. Use of telecommunications and computers to transfer the risk? b. Lower rates and less service? 8. How have changes in reinsurance pricing affected ceding company pricing?

Description: September 2015 Reinsurance News

Description: This 1981 session focused on Reinsurance Trends. Questions included: i. Why the recent movement from YRT to Coinsurance? 2. Should a company use a bulk or self-administered system? 3. When is it advantageous to use Coinsurance or modified coinsurance on existing business for tax planning 4. Experimental Underwriting - what are the results? 5. Pricing assumptions - where have all the margins gone? 6. When can reinsurance pools be used effectively what are the pitfalls? 7. What's in the future? a. Use of telecommunications and computers to transfer the risks? b. Lower rates and less service? 8. How have changes in reinsurance pricing affected ceding company pricing?

Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments

Description: The article discusses ways smaller companies might improve their ability to form a mutually satisfying relationship with their reinsurers by considering the perspective/needs of the reinsurer.

Description: Ceding companies must react appropriately to changes in the substandard reinsurance market to avoid losses. By using the substandard/insurance pricing algorithms presented in this paper, ceding companies may develop an effective placement method and thereby avoid potential future losses. From the Actuarial Research Clearing House 1994 Vol. 2 .